New AS drug approved by FDA
Just sharing—article from 9/30/24:
FDA approves bimekizumab, now Bimzelx, for active AS and nr-axSpA Treatment is antibody-based therapy to block IL-17A, IL-17F proteins
Data from the completed Phase 2b BE AGILE trial (NCT02963506) and its open-label extension study (NCT03355573) demonstrated Bimzelx’s long-term efficacy in AS. Results showed that up to five years of treatment safely led to sustained reductions in disease activity and symptoms and improvements in physical function and life quality.
“The U.S. rheumatology community welcomes the approval of [Bimzelx] for use across the entire spectrum of axial spondyloarthritis, especially given that there are few options approved currently to treat both nonradiographic axial spondyloarthritis and ankylosing spondylitis,”